Core H: Neuroimaging Core

摘要：神经成像核心 脑结构、功能和代谢的体内神经成像评估提供了有力的 与分子生物标志物数据互补的机制数据。神经影像学核心使命是支持 通过降低研究人员对广泛的神经成像能力的障碍来进行新颖的研究。的 Neuroimaging Core通过提供初步研究概念化和 设计、获取和分析协议，并协助数据解释、手稿和赠款 应用.神经成像核心还开发了积极部署的新成像方法 在ADRC网络中进行多中心临床试验。核心人员指导下一代科学家 并协助其他领域的研究人员开展对AD、衰老和神经退行性疾病的研究。 神经影像学核心管理来自临床队列和研究者的可共享图像数据集- 启动研究，并将摘要数据发送到数据管理和统计核心， 策划的临床（临床核心）、遗传和生物标志物（生物标志物核心）和组织学（神经病理学 核心）数据库，与研究者共享，以促进进一步研究。在目前的资金 在这一周期内，这些努力促成了与26名既定调查员和9名K奖获得者的合作， 支持73个受资助项目，产生39份同行评审的手稿。 在下一个周期中，我们将继续这些努力，并添加两个新功能。神经血管成像将 允许探索导致AD和神经退行性变的血管机制，增加了一种新的 将“V”生物标志物成像到ATN（MV）。深入的表型分析将从丰富的 我们的ADRC从我们的研究中积累的综合临床、遗传、行为、生物标志物和成像数据， 临床队列。我们提出了与国家阿尔茨海默病项目ACT（NAPA）主题相一致的三个目标： 目标1.支持现有和未来研究人员在AD和衰老研究中的成像工作。的 Neuroimaging Core将支持新研究的设计和实施，提供安全、可访问的图像 存储、标准化分析管道和将成像应用于ADRD的培训。我们将提供标准 基于图像的ATN表型数据用于临床队列的病因诊断。我们会推广使用 协调成像采集，以增加研究者与SCAN等网络之间的数据共享 和ADNI。 目标2.为AD和衰老研究开发新的成像技术。神经成像核心将 开发新的成像采集和分析技术，并通过建立 神经血管成像和深层表型分析作为KU ADRC的新功能。 目标3。在本地和整个ADC网络中共享和实施成像方法和数据。的 Neuroimaging Core将积极分享整合的成像数据、深度表型分析能力和其他新颖的 ADRC网络中的方法，以支持临床前到多中心临床试验的全方位。

ABSTRACT: NEUROIMAGING CORE In vivo neuroimaging assessment of brain structure, function, and metabolism provides powerful mechanistic data complementary to molecular biomarker data. The Neuroimaging Core mission is to support novel research by lowering the barriers for investigators to a wide array of neuroimaging capabilities. The Neuroimaging Core facilitates the use of MRI and PET imaging by providing initial study conceptualization and design, acquisition and analysis protocols, and assistance with data interpretation, manuscripts, and grant applications. The Neuroimaging Core also develops novel imaging methods which are actively deployed across the ADRC network in multisite clinical trials. Core personnel mentor the next generation of scientists and assist established investigators from other fields to initiate studies into AD, aging, and neurodegeneration. The Neuroimaging Core curates a dataset of shareable images from the Clinical Cohort and investigator- initiated studies and sends summary data to the Data Management and Statistics Core for addition to the curated clinical (Clinical Core), genetic and biomarker (Biomarker Core), and histological (Neuropathology Core) database which is shared with investigators for stimulating further study. During the current funding cycle, these efforts have resulted in collaborations with 26 established investigators and nine K-awardees and support for 73 funded projects resulting in 39 peer-reviewed manuscripts. In the next cycle, we will continue these efforts and add two novel capabilities. Neurovascular imaging will allow explorations of the vascular mechanisms contributing to AD and neurodegeneration, adding a novel imaging “V” biomarker to ATN(MV). Deep phenotyping will yield novel testable hypotheses from the rich integrated clinical, genetic, behavioral, biomarker and imaging data that our ADRC is accumulating from our Clinical Cohort. We propose three aims aligned with the National Alzheimer's Project ACT (NAPA) themes: Aim 1. Support imaging efforts of existing and future investigators in AD and aging research. The Neuroimaging Core will support design and implementation of new studies, provide secure, accessible image storage, standardized analysis pipelines, and training to apply imaging to ADRD. We will provide standard image-based ATN phenotype data for etiologic diagnosis of the Clinical Cohort. We will promote the use of harmonized imaging acquisitions to increase data sharing between investigators and networks such as SCAN and ADNI. Aim 2. Develop novel imaging techniques for AD and aging research. The Neuroimaging Core will develop new imaging acquisition and analysis techniques and stimulate new research by establishing neurovascular imaging and deep phenotyping as novel new capabilities in the KU ADRC. Aim 3. Share and implement imaging methods and data locally and across the ADC network. The Neuroimaging Core will actively share integrated imaging data, deep phenotyping capabilities, and other novel methods across the ADRC network in support of the full spectrum of preclinical to multisite clinical trials.